David T. Dexter
YOU?
Author Swipe
View article: Treatment Selection and Prioritization for the <scp>EJS ACT</scp>‐<scp>PD MAMS</scp> Trial Platform
Treatment Selection and Prioritization for the <span>EJS ACT</span>‐<span>PD MAMS</span> Trial Platform Open
Background There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment o…
View article: Stereological analysis of cholinergic neurons within bilateral pedunculopontine nuclei in health and when affected by Parkinson's disease
Stereological analysis of cholinergic neurons within bilateral pedunculopontine nuclei in health and when affected by Parkinson's disease Open
During Parkinson's disease (PD), loss of brainstem‐based pedunculopontine nucleus' (PPN) cholinergic neurons induces progressive postural‐gait disability (PGD). PPN‐deep brain stimulation inconsistently alleviates PGD, due to stereotactic …
View article: A framework to standardize gait study protocols in Parkinson's disease
A framework to standardize gait study protocols in Parkinson's disease Open
Background Research over the past twenty years has shown that gait outcomes have a high sensitivity for diagnosing Parkinson's disease (PD), for detecting the effects of interventions, and for monitoring disease progression, even in early …
View article: A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders Open
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) share underlying neuropathology. Despite overlapping biology, therapeutic development has been approached separately for these clinical syndromes and there remains no treatment t…
View article: Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances Open
Novel therapies with the ability to delay disease progression are a gap in the care of people living with Parkinson disease (PD) today. Clinical outcomes assessments (COAs) that are sensitive to the earliest clinical changes in PD are deem…
View article: Interim Two-Year Outcomes Following Mechanical Thrombectomy for Deep Vein Thrombosis from the Real-World CLOUT Registry
Interim Two-Year Outcomes Following Mechanical Thrombectomy for Deep Vein Thrombosis from the Real-World CLOUT Registry Open
Endovascular approaches are increasingly implemented in the treatment of lower extremity deep vein thrombosis (DVT), despite a lack of long-term data. The CLOUT Registry is a prospective, all-comer evaluation of patients with DVT treated w…
View article: Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative Open
In 2011, the UK medical research charity Cure Parkinson’s set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson’s disease (PD). The f…
View article: Neuroprotective role for RORA in Parkinson’s disease revealed by analysis of post-mortem brain and a dopaminergic cell line
Neuroprotective role for RORA in Parkinson’s disease revealed by analysis of post-mortem brain and a dopaminergic cell line Open
Parkinson’s disease (PD) is almost twice as prevalent in men, which has largely been attributed to neuroprotective effect of oestradiol in women. RORA (retinoic acid receptor-related orphan receptor alpha) regulates the transcription of ce…
View article: Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease Open
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the oncology field, by the use of multi-arm, multi-stage trials allowing the evaluation of multiple therapeutic candidates simultaneously, and se…
View article: The key to a megacity: Information
The key to a megacity: Information Open
The key to a megacity: InformationA recent addition to aggregating mobile, social, and location is Ushahidi, a platform that unifies data gathered from multiple sources (SMS, email, web) and distributes it onto a visual map or timeline.Thi…
View article: Trial of Deferiprone in Parkinson’s Disease
Trial of Deferiprone in Parkinson’s Disease Open
In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with pl…
View article: Automatic Sample Segmentation & Detection of Parkinson’s Disease Using Synthetic Staining & Deep Learning
Automatic Sample Segmentation & Detection of Parkinson’s Disease Using Synthetic Staining & Deep Learning Open
The identification of Parkinson’s Disease (PD) from post-mortem brain slices is time consuming for highly trained neuropathologists, often taking many hours per case. In this study, we demonstrate fully automatic PD detection, from single …
View article: Iron, Neuroinflammation and Neurodegeneration
Iron, Neuroinflammation and Neurodegeneration Open
Disturbance of the brain homeostasis, either directly via the formation of abnormal proteins or cerebral hypo-perfusion, or indirectly via peripheral inflammation, will activate microglia to synthesise a variety of pro-inflammatory agents …
View article: Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials
Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials Open
[This corrects the article DOI: 10.2196/23011.].
View article: Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials (Preprint)
Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials (Preprint) Open
UNSTRUCTURED REMOVE
View article: A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation Open
Leucine‐rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson’s disease (PD). Understanding the rate of progression in PD as measured by both motor and nonmotor feat…
View article: Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?
Is Chelation Therapy a Potential Treatment for Parkinson’s Disease? Open
Iron loading in some brain regions occurs in Parkinson’s Disease (PD), and it has been considered that its removal by iron chelators could be an appropriate therapeutic approach. Since neuroinflammation with microgliosis is also a common f…
View article: Data Sharing Goals for Nonprofit Funders of Clinical Trials
Data Sharing Goals for Nonprofit Funders of Clinical Trials Open
Sharing clinical trial data can provide value to research participants and communities by accelerating the development of new knowledge and therapies as investigators merge data sets to conduct new analyses, reproduce published findings to…
View article: Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science Open
Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disea…
View article: Data Sharing Goals for Nonprofit Funders of Clinical Trials (Preprint)
Data Sharing Goals for Nonprofit Funders of Clinical Trials (Preprint) Open
UNSTRUCTURED Sharing clinical trial data can provide value to research participants and communities by accelerating the development of new knowledge and therapies as investigators merge data sets to conduct new analyses, reproduce publish…
View article: GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop Open
The concept of repairing the brain with growth factors has been pursued for many years in a variety of neurodegenerative diseases including primarily Parkinson's disease (PD) using glial cell line-derived neurotrophic factor (GDNF). This n…
View article: Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson’s disease
Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson’s disease Open
Ubiquitin proteasome system (UPS) impairment, excessive cellular oxidative stress, and iron dyshomeostasis are key to substantia nigra dopaminergic neuronal degeneration in Parkinson's disease (PD); however, a link between these features r…
View article: Supplementary Material for: Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science
Supplementary Material for: Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science Open
Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disea…
View article: Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs
Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs Open
A quantitative assessment of Parkinson's disease (PD) progression is critical for optimizing clinical trials design. Disease progression model was developed using pooled data from the Progression Marker Initiative study and the Incidence o…